Equifax Inc. logo

Equifax Inc. (EFX)

Market Open
15 Jun, 18:31
NYSE NYSE
$
165. 17
+1.46
+0.8918%
$
20.31B Market Cap
57.83 P/E Ratio
2.24% Div Yield
736,609 Volume
6.64 Eps
$ 163.71
Previous Close
Add Transaction
Day Range
164.14 168.31
Year Range
153.91 275.91
Want to track EFX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Equifax (EFX) Surpasses Q4 Earnings Estimates

Equifax (EFX) Surpasses Q4 Earnings Estimates

Equifax (EFX) came out with quarterly earnings of $2.12 per share, beating the Zacks Consensus Estimate of $2.10 per share. This compares to earnings of $1.81 per share a year ago.

Zacks | 1 year ago
Equifax Gears Up to Report Q4 Earnings: What's in the Offing?

Equifax Gears Up to Report Q4 Earnings: What's in the Offing?

EFX's fourth-quarter 2024 revenues are expected to have increased due to healthy mortgage activities.

Zacks | 1 year ago
Ahead of Equifax (EFX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Ahead of Equifax (EFX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Equifax (EFX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks | 1 year ago
Equifax (EFX) Earnings Expected to Grow: Should You Buy?

Equifax (EFX) Earnings Expected to Grow: Should You Buy?

Equifax (EFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3 MASH patients, with data expected in the first half of 2026 and 2027, respectively.

Seekingalpha | 1 year ago
Equifax to Settle CFPB Allegations That It Didn't Ensure Accuracy of Credit Reports

Equifax to Settle CFPB Allegations That It Didn't Ensure Accuracy of Credit Reports

Equifax has agreed to a settlement and consent order that will resolve Consumer Financial Protection Bureau (CFPB) allegations that the consumer reporting agency failed to take steps to ensure the accuracy of its credit reports.

Pymnts | 1 year ago
US consumer bureau fines Equifax $15 million for issues fixing consumer disputes

US consumer bureau fines Equifax $15 million for issues fixing consumer disputes

The U.S. Consumer Financial Protection Bureau announced on Friday it had fined credit reporting bureau Equifax $15 million for failing to sufficiently investigate consumer disputes of its credit reports.

Reuters | 1 year ago
The 'New Equifax' Will Be More Profitable On New Cloud

The 'New Equifax' Will Be More Profitable On New Cloud

Equifax's transition to its own cloud and EFX.AI capabilities will drive revenue growth, margin expansion, and increased free cash flow, enhancing profitability. Lower CapEx and higher margins will boost earnings, with EPS expected to grow significantly, supporting a one-year price target of $306.75 and a Strong Buy rating. The new cloud platform will improve productivity, benefiting shareholders with increased returns.

Seekingalpha | 1 year ago
Equifax Benefits From Strategic Buyouts Amid Declining Liquidity

Equifax Benefits From Strategic Buyouts Amid Declining Liquidity

EFX stock is gaining from the services provided to its huge client base and product portfolio, which keeps the company ahead of its peers.

Zacks | 1 year ago
Equifax and Mastercard Partner on Fraud Management in Latin America

Equifax and Mastercard Partner on Fraud Management in Latin America

Equifax and Mastercard have partnered to provide fraud management tools to businesses in Latin America, excluding Brazil. This collaboration will make these tools available to Mastercard business customers in Latin America — including financial institutions, payment service providers, acquiring banks and merchants — through Equifax's Kount Payment Fraud solution, the companies said in a Thursday (Dec. 5) press release.

Pymnts | 1 year ago
Is the Options Market Predicting a Spike in Equifax (EFX) Stock?

Is the Options Market Predicting a Spike in Equifax (EFX) Stock?

Investors need to pay close attention to Equifax (EFX) stock based on the movements in the options market lately.

Zacks | 1 year ago
Here's Why You Should Retain Equifax Stock in Your Portfolio Now

Here's Why You Should Retain Equifax Stock in Your Portfolio Now

EFX is leveraging acquisitions to expand its presence around the globe, and assist its customers to cater to their employment and hiring needs.

Zacks | 1 year ago
Loading...
Load More